Published in Proc Natl Acad Sci U S A on November 20, 2012
Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal (2014) 1.29
A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci (2013) 1.11
Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol (2013) 0.96
Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal (2013) 0.94
Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med (2016) 0.93
Frataxin directly stimulates mitochondrial cysteine desulfurase by exposing substrate-binding sites, and a mutant Fe-S cluster scaffold protein with frataxin-bypassing ability acts similarly. J Biol Chem (2013) 0.93
Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Front Pharmacol (2014) 0.91
Frataxin-bypassing Isu1: characterization of the bypass activity in cells and mitochondria. Biochem J (2014) 0.86
Missense mutations linked to friedreich ataxia have different but synergistic effects on mitochondrial frataxin isoforms. J Biol Chem (2012) 0.85
Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia. Br J Pharmacol (2014) 0.83
Mössbauer study and modeling of iron import and trafficking in human jurkat cells. Biochemistry (2013) 0.82
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol (2014) 0.78
Insertion mutants in Drosophila melanogaster Hsc20 halt larval growth and lead to reduced iron-sulfur cluster enzyme activities and impaired iron homeostasis. J Biol Inorg Chem (2013) 0.77
Speciation of iron in mouse liver during development, iron deficiency, IRP2 deletion and inflammatory hepatitis. Metallomics (2014) 0.77
Mitochondrial iron overload: causes and consequences. Curr Opin Genet Dev (2016) 0.76
Loss of Frataxin induces iron toxicity, sphingolipid synthesis, and Pdk1/Mef2 activation, leading to neurodegeneration. Elife (2016) 0.76
Synthesis, delivery and regulation of eukaryotic heme and Fe-S cluster cofactors. Arch Biochem Biophys (2016) 0.75
Magnetic mapping of iron in rodent spleen. Nanomedicine (2016) 0.75
Mössbauer Spectra of Mouse Hearts Reveal Age-dependent Changes in Mitochondrial and Ferritin Iron Levels. J Biol Chem (2017) 0.75
Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45
Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet (2001) 3.10
Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J (2004) 2.22
Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 2.18
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A (2010) 2.02
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet (2003) 1.99
Cardiac copper deficiency activates a systemic signaling mechanism that communicates with the copper acquisition and storage organs. Cell Metab (2010) 1.98
Intestinal ferritin H is required for an accurate control of iron absorption. Cell Metab (2010) 1.69
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism. Blood (1996) 1.18
Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol (2003) 1.10
Ferritin and hemosiderin in pathological tissues. Electron Microsc Rev (1992) 1.01
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol (2012) 1.00
Energy-dispersive X-ray analysis of the mitochondria of sideroblastic anaemia. Br J Haematol (1980) 0.98
Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis. Biochim Biophys Acta (1982) 0.92
The form of iron oxide deposits in thalassemic tissues varies between different groups of patients: a comparison between Thai beta-thalassemia/hemoglobin E patients and Australian beta-thalassemia patients. Biochim Biophys Acta (1998) 0.89
Co-precipitation of phosphate and iron limits mitochondrial phosphate availability in Saccharomyces cerevisiae lacking the yeast frataxin homologue (YFH1). J Biol Chem (2010) 0.88
Quantitative magnetic analysis reveals ferritin-like iron as the most predominant iron-containing species in the murine Hfe-haemochromatosis. Biochim Biophys Acta (2012) 0.81
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood (2004) 4.40
Iron overload in human disease. N Engl J Med (2012) 3.77
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst (2008) 2.29
The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev (2005) 2.22
Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood (2004) 2.12
Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A (2010) 2.02
Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood (2004) 2.00
Novel diaroylhydrazine ligands as iron chelators: coordination chemistry and biological activity. J Biol Inorg Chem (2005) 1.96
The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta (2002) 1.86
Biological applications of magnetic nanoparticles. Chem Soc Rev (2012) 1.76
New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr (2004) 1.71
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood (2004) 1.67
A sub-microscopic gametocyte reservoir can sustain malaria transmission. PLoS One (2011) 1.67
Iron uptake and metabolism in the new millennium. Trends Cell Biol (2006) 1.66
Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood (2004) 1.62
Direct interorganellar transfer of iron from endosome to mitochondrion. Blood (2007) 1.59
Heme oxygenase 1 is expressed in murine erythroid cells where it controls the level of regulatory heme. Blood (2014) 1.59
XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol (2006) 1.58
The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis (2006) 1.49
N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One (2013) 1.46
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem (2009) 1.43
Growth arrest and DNA damage-45 alpha (GADD45alpha). Int J Biochem Cell Biol (2008) 1.43
The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol (2002) 1.40
Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol (2003) 1.38
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
The long history of iron in the Universe and in health and disease. Biochim Biophys Acta (2011) 1.33
Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. Proc Natl Acad Sci U S A (2009) 1.31
Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res (2003) 1.30
Complexes of cytotoxic chelators from the dipyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. Inorg Chem (2006) 1.30
Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood (2002) 1.29
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res (2006) 1.28
Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res (2011) 1.28
Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A (2009) 1.25
Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25
Crusade for iron: iron uptake in unicellular eukaryotes and its significance for virulence. Trends Microbiol (2008) 1.24
The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. Proc Natl Acad Sci U S A (2008) 1.22
Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol (2010) 1.21
Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol (2010) 1.21
Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood (2009) 1.18
Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallogr C (2003) 1.17
Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem (2005) 1.17
The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis (2011) 1.17
S-nitrosylation of IRP2 regulates its stability via the ubiquitin-proteasome pathway. Mol Cell Biol (2004) 1.16
Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal (2012) 1.16
Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood (2006) 1.15
Nitrogen monoxide-mediated control of ferritin synthesis: implications for macrophage iron homeostasis. Proc Natl Acad Sci U S A (2002) 1.14
Tuning cell cycle regulation with an iron key. Cell Cycle (2007) 1.13
The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J (2009) 1.12
Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol (2004) 1.11
Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology (2007) 1.11
Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol (2011) 1.11
Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy. Chem Res Toxicol (2007) 1.10
The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal (2012) 1.09
The prolyl 4-hydroxylase inhibitor ethyl-3,4-dihydroxybenzoate generates effective iron deficiency in cultured cells. FEBS Lett (2002) 1.09
A comparative study of a flow-cytometry-based assessment of in vitro Plasmodium falciparum drug sensitivity. Malar J (2009) 1.08
The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol (2012) 1.08
Hypoxia. 5. Hypoxia and hematopoiesis. Am J Physiol Cell Physiol (2011) 1.07
Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab (2013) 1.06
Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. Proc Natl Acad Sci U S A (2006) 1.06
Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem (2010) 1.05
Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1 alpha and p53. Mol Pharmacol (2009) 1.05
Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood (2004) 1.03
Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci (2009) 1.03
Thiosemicarbazones: the new wave in cancer treatment. Future Med Chem (2009) 1.03
In vivo tumor growth is inhibited by cytosolic iron deprivation caused by the expression of mitochondrial ferritin. Blood (2006) 1.02
The translational regulator eIF3a: the tricky eIF3 subunit! Biochim Biophys Acta (2010) 1.02
P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem (2013) 1.01
Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochim Biophys Acta (2013) 1.00
Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorg Med Chem Lett (2012) 0.99
Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy. Bioorg Med Chem Lett (2012) 0.99
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. J Med Chem (2007) 0.98
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem (2011) 0.98
Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism: mirror-image effector molecules that target iron. Biochem J (2003) 0.98
Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem (2009) 0.96
Investigating biological activity spectrum for novel quinoline analogues. Bioorg Med Chem (2006) 0.96